Wednesday, 26 August 2026European Markets

OREGE Stock Went Up By Over 11% So Far Today

Loading stream...

(vianews) - shares of orege (cac 40: orege.pa) rose by a staggering 11.76% to €0.29 at 14:06 est on monday, after five successive sessions in a row of losses. cac 40 is dropping 0.33% to €7,467.49, after two successive sessions in a row of gains. this seems, up until now, a somewhat bearish trend trading session today.

orege's last close was €0.26, 68.9% below its 52-week high of €0.82.

about orege

orege société anonyme designs, develops, operates, manufactures, and markets municipal and industrial sludge, and effluents treatment solutions in france, the united states, japan, germany, and the united kingdom. the company offers slg solution for conditioning, treating, and recovering municipal and industrial sludge; slg-f, a combination of slg conditioning solution; and flosep for sludge separation and thickening tool. it also provides after-sales, installation and commissioning, operator training, warranty extensions, maintenance, and process line optimization services. the company was incorporated in 2005 and is headquartered in voisins-le-bretonneux, france. orege société anonyme is a subsidiary of eren groupe sa.

earnings per share

as for profitability, orege has a trailing twelve months eps of €-0.1.

sales growth

orege's sales growth for the current quarter is 87.4%.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com